Nutlin-3

目录号:S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。

规格 价格 库存 购买数量  
RMB 1515.15 现货
RMB 900.36 现货
RMB 1407.13 现货
RMB 3026.07 现货
RMB 7939.67 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。
靶点
Mdm2 [5]
(Cell-free assay)
180 nM
体外研究

Nutlin-3有效抑制MDM2-p53相互作用,IC50 为 90 nM, 导致p53通路激活。Nutlin-3 处理含野生型p53的细胞,如HCT116, RKO 和SJSA-1,诱导MDM2 和p21表达, 且具有有效的抗增殖活性,IC50 为~1.5 μM, 但是作用于含突变型p53的细胞系 SW480和 MDA-MB-435没有效果。10 μM Nutlin-3处理 SJSA-1细胞48小时,显著诱导caspase依赖的细胞凋亡,凋亡达~45%。虽然Nutlin-3也抑制人皮肤 (1043SK) 和小鼠胚胎 (NIH/3T3) 的生长和活力,IC50分别为2.2 μM 和1.3 μM, 10 μM Nutlin-3处理一周后仍保留细胞活力,而3 μM Nutlin-3 处理SJSA-1细胞后,细胞则无活力。[1] Nutlin-3 不诱导p53在关键丝氨酸残基的磷酸化,在特定DNA结合序列没有区别,且与基因毒性药物Doxorubicin和Etoposide诱导的磷酸化p53相比, 使p53靶点基因转活,说明 p53 在关键丝氨酸残基的磷酸化对转录激活和凋亡是非必需的。[2] 虽然与MDM2相比,Nutlin-3 与MDMX 结合的效率低一点, Nutlin-3作用于视网膜母细胞瘤细胞(Weri1),能抑制MDMX–p53相互作用,且诱导 p53通路,IC50为0.7 μM。[3] 30 μM Nutlin-3作用于无野生型p53的细胞,也扰乱内源性p73-HDM2 相互作用,且增强p73稳定性和促凋亡活性, 导致细胞生长受抑制,和诱导凋亡。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu1xsDPxE1? NVPh[YhjPDkEoHi= MnPRZoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ NILhNpEzPjN3MEW2OS=>
NP69 NIDQ[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNzLk[5xtEzNjV2IN88US=> NFK3XJgzPjJ3MkW3OS=>
NP460 NFTTNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHwTWM2OD1{Mj64OeKyOS5zODFOwG0> MYOyOlI2OjV5NR?=
C666-1 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3iTHZQUUN3ME2xPU46PcLzOD65N{DPxE1? MWCyOlI2OjV5NR?=
C666-1 MkLDR4VtdCCYaXHibYxqfHliQYPzZZk> MYOxNEDDvU1? MoGyOFghcA>? MX;EUXNQ MUfz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzD0bIUh[3m2b4TvfIlkKGWoZnXjeEBw\iClaYPwcIF1cW5? MlTVNlYzPTJ3N{W=
C666-1  MWnGeY5kfGmxbjDBd5NigQ>? MUSxNEDDvU1? MXmyOEBp NETQUpZFVVOR MYrhZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> M3OyelI3OjV{NUe1
C666-1 MojvRZBweHSxc3nzJGF{e2G7 M2HhXVExKML3TR?= Mn\4OFgwPzJiaB?= M2f3PGROW09? MYPz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= M1vI[|I3OjV{NUe1
A549 M2P0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfRV25MOjRiaB?= M4HvWmlEPTB;MUeuOlghyrFiND61NkDPxE1? Mk\JNlYyOjV{M{C=
A549-NTC Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TGPFI1KGh? NUDzUHh5UUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= MUWyOlEzPTJ|MB?=
A549-920 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfGZ49{OjRiaB?= NICzeFFKSzVyPUOzMlg2KMLzIESuPFQh|ryP MWiyOlEzPTJ|MB?=
CRL-5908 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\BNHU{OjRiaB?= M1fZOWlEPTB;M{iuO|EhyrFiMj60N{DPxE1? MWSyOlEzPTJ|MB?=
L6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT5bYUyOMLizszNxsA> NVe5W3ByOjRxNEivO|IhcA>? M1nk[2ROW09? MnHabY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v MoL5NlU5PzF5OUS=
C2C12 MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxNOKh|ryPwrC= MorBNlQwPDhxN{KgbC=> M161OmROW09? NIj6bGxqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? MVeyOVg4OTd7NB?=
MCF-7  MmnnSpVv[3Srb36gRZN{[Xl? NVuw[G9EOTEEoN88US=> MlnMSG1UVw>? MmLBbY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh NFLO[VQzPTdyMkewNy=>
DU4475  NYjiOppITnWwY4Tpc44hSXO|YYm= MnjjOU8yOC9{MDFOwG0> NIjLO2szPMLiaB?= M4jGUIRwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> MoTONlU2PDdzN{S=
SMMC-7721 MmXWSpVv[3Srb36gRZN{[Xl? MWqxNEDPxE1? MVK0PEBp M2LteGROW09? MXPjZZV{\XNiRF7BJGRUSiCmYX3h[4U> Mo[2NlU2PDR|NkG=
SMMC-7721 MnH5SpVv[3Srb36gRZN{[Xl? MnuwNVAh|ryP MV[0PEBp MkHnSG1UVw>? MXrpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg Mn3qNlU2PDR|NkG=
SMMC-7721 NWXZZlYxTnWwY4Tpc44hSXO|YYm= NFPlWJcyOCEQvF2= M{\5SFQ5KGh? MlPLSG1UVw>? MVfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B NFXUW3gzPTV2NEO2NS=>
SMMC-7721 MV\GeY5kfGmxbjDBd5NigQ>? NIHzfmoyOCEQvF2= MoXWN|YhcA>? NFPPWJFFVVOR MXXjZZV{\XNidHjlJIVkfG:yaXOg[ZhxemW|c3nvckBw\iCLRlmxOi=> NHXZS2QzPTV2NEO2NS=>
MCF-7 NGTuZpFHfW6ldHnvckBCe3OjeR?= NW\NeXV[OTEEoN88US=> MYWwMVI1KGh? NYKxXFRtcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx MV2yOVQ5OjN5Mx?=
OVCAR10 MXvGeY5kfGmxbjDBd5NigQ>? NYq0V3F5OTEEoN88US=> NWe3OHhVOjGqwrC= M2DFRmROW09? MVvpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M3;GZ|I2PDJ4NUS4
NCI-H23 M2Pp[2Z2dmO2aX;uJGF{e2G7 MV:xNOKh|ryP MlXZNlFpyqB? MmrjSG1UVw>? MmTHbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> M3TodFI2PDJ4NUS4
A2780 NFT3SZFHfW6ldHnvckBCe3OjeR?= MYWxNOKh|ryP M16yPFIycMLi NG\qXGJFVVOR NFnnRnZqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MUiyOVQzPjV2OB?=
NCI-H23 Ml7FSpVv[3Srb36gRZN{[Xl? MVWxNOKh|ryP MVKyNYjDqA>? NGXrbm1FVVOR M{DKV4Rm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz NIPBOlQzPTR{NkW0PC=>
A2780 NXvhTG01TnWwY4Tpc44hSXO|YYm= MYCxNOKh|ryP Ml;GNlFpyqB? NHjmepNFVVOR MoTt[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= MnT3NlU1OjZ3NEi=
HCT116  NXvQOnNyTnWwY4Tpc44hSXO|YYm= MnfFNVAhyrWP M2\iU|I1KGh? MXHjZZV{\XNiYTDwOVMu\GWyZX7k[Y51KHSndILhdIxwcWRiR{GtZZJz\XO2IHnuJIRqeGyxaXSgTGNVOTF4IHPsc45meyCGMzDhcoQhTDh? NUnwXo0xOjV|OECwOVU>
MCF-10CA1a MXfGeY5kfGmxbjDBd5NigQ>? NWLQWFZQOTEEoN88US=> M{DuNFQ5KGh? MVjEUXNQ NF3GNJRqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| Mnm5NlUzPTd5Mkm=
MCF-10A1  MV;GeY5kfGmxbjDBd5NigQ>? NG\oXYoyOMLizszN NY\5NGhYOjRxNEigbC=> MVzEUXNQ M1XBbIlvcGmkaYTzJI1q\3KjdHnvckBw\iCwb4LtZYwh[nKnYYP0JIVxcXSqZXzpZYzDqA>? NV7pSIU2OjV{NUe3Nlk>
MCF-10CA1a NHvDbG9HfW6ldHnvckBCe3OjeR?= NELu[HoyOMLizszN MYeyOEBp MoLRSG1UVw>? NVLjXlA6\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= M3WyU|I2OjV5N{K5
MCF-10CA1a M3nxUWZ2dmO2aX;uJGF{e2G7 MUexNOKh|ryP NF\6OoczPCCq M17FSmROW09? MoLjbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MWWyOVI2Pzd{OR?=
SK-BR-7 NV3NcVdbTnWwY4Tpc44hSXO|YYm= MnTCNVDDqM7:TR?= M3fVRVI1KGh? MljYSG1UVw>? NHW2e2ZqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M{TocFI2OjV5N{K5
SUM102PT NEC4NoZHfW6ldHnvckBCe3OjeR?= NUW2[5hyOTEEoN88US=> MoG4NlQhcA>? M2\6TWROW09? Ml;hbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MXyyOVI2Pzd{OR?=
RAW 264.7 NVXYUYhvTnWwY4Tpc44hSXO|YYm= NXvWT2FWOTEEoN88US=> MXKzNEBucW5? NGXlNHNxemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> NFLNfWQzPTF5MkW0Oy=>
RAW 264.7 MVPGeY5kfGmxbjDBd5NigQ>? NEHhT3kyOMLizszN NFH6fGQ{OCCvaX6= Mo[ydoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= NGrjRogzPTF5MkW0Oy=>
RAW 264.7 NULDSmlYTnWwY4Tpc44hSXO|YYm= NHLMfnoyOMLizszN NWH5VGFqOzBibXnu MYnpcohq[mm2czDMVHMucW6mdXPl[EBPVyCycn;keYN1cW:wwrC= MmrENlUyPzJ3NEe=
MCF7  MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlXHNk42KML3TR?= NIrwXFk2KGR? NUmybnZ{TE2VTx?= NXPQd2VKe2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> NGTEWpozPTB6NUmwNi=>
MCF7  NYCyOWRPTnWwY4Tpc44hSXO|YYm= MoXJNk42KML3TR?= M3rye|Q5KGh? MkHZSG1UVw>? M{Tj[YRm[3KnYYPld{B1cGViaH;tc4xw\2:3czDEV2IhemWyYXnyJIZz\XG3ZX7jbYV{ NVv5RXlEOjVyOEW5NFI>
ACHN MmDLR4VtdCCYaXHibYxqfHliQYPzZZk> M3Tv[FAvPS1zMDFOwG0> MWSwMVYh\A>? MVTEUXNQ MVHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MljTNlUxPjd5OEe=
Caki-2 NVPBVFliS2WubDDWbYFjcWyrdImgRZN{[Xl? NFTEWFcxNjVvMUCg{txO Mn;FNE03KGR? MWnEUXNQ MnzCbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFuxcWIzPTB4N{e4Oy=>
A498 NVfY[4V5S2WubDDWbYFjcWyrdImgRZN{[Xl? NVnBR49VOC53LUGwJO69VQ>? MoTvNE03KGR? MX3EUXNQ NYrhWmVScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYizRWxGOjVyNke3PFc>
115 MnfqR4VtdCCYaXHibYxqfHliQYPzZZk> M4X5WVAvPS1zMDFOwG0> NUPqTI9uOC14IHS= NIn4S2VFVVOR NIq2[5VqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH;1TlYzPTB4N{e4Oy=>
117 NELPbIhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFvZSIkxNjVvMUCg{txO NVP4RoI5OC14IHS= MkjYSG1UVw>? M13NUolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHf0[lczPTB4N{e4Oy=>
ACHN M1TYSGZ2dmO2aX;uJGF{e2G7 MlHRNE42NzFxNTFOwG0> NYTNdVhtPDhiaB?= M2DyfmROW09? M33JcIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MVeyOVA3Pzd6Nx?=
Caki-2 MlPXSpVv[3Srb36gRZN{[Xl? MX2wMlUwOS93IN88US=> MUm0PEBp NXyxOnVVTE2VTx?= NVm2VJpxdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NYLqVWh{OjVyNke3PFc>
A498 MoToSpVv[3Srb36gRZN{[Xl? NE\EbYwxNjVxMT:1JO69VQ>? MmfNOFghcA>? NIfqO|ZFVVOR MXjs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MWKyOVA3Pzd6Nx?=
115 NHeyUIVHfW6ldHnvckBCe3OjeR?= NFS5PZIxNjVxMT:1JO69VQ>? M2C4[FQ5KGh? NI[zeoRFVVOR MUjs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MXWyOVA3Pzd6Nx?=
ACHN MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\hflUh|ryP NIrUOpE1QCCq MkKxSG1UVw>? NF3NdJhqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NX\qSVJvOjVyNke3PFc>
Caki-2 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXEbFdVPSEQvF2= NG[4XJU1QCCq NG\MNYxFVVOR NV3JXpJGcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh NWP4bIpyOjVyNke3PFc>
A498 NV;rTXVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC1JO69VQ>? NV2xcWtPPDhiaB?= M1XOVGROW09? MV\pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NXfJNnM3OjVyNke3PFc>
115 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GzVlUh|ryP MlvUOFghcA>? NUT1S4NWTE2VTx?= NVXJ[oxpcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh M1fzUlI2ODZ5N{i3
ACHN M1:4UGZ2dmO2aX;uJGF{e2G7 NGnLbHo2KM7:TR?= MonqOFghcA>? NFHjd29FVVOR NYPCUnlvcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MnjJNlUxPjd5OEe=
Caki-2 NIrpO2VHfW6ldHnvckBCe3OjeR?= NXPi[5NGPSEQvF2= MUm0PEBp MlziSG1UVw>? MVnpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M{DoUVI2ODZ5N{i3
A498 NELUeIZHfW6ldHnvckBCe3OjeR?= NFTSZXU2KM7:TR?= M1:5ZlQ5KGh? NIDXT3hFVVOR M3jCN4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NGTjRmQzPTB4N{e4Oy=>
115 Mk\PSpVv[3Srb36gRZN{[Xl? Mn\QOUDPxE1? NX\zWlF5PDhiaB?= MkjqSG1UVw>? M3LPTolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M{DC[lI2ODZ5N{i3
MOLM-13 MoDDSpVv[3Srb36gRZN{[Xl? MoTROuKh|ryP M3rtbFAuQCCq MWLEUXNQ NUTYUYxjcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| M3;Z[|I1QDh3MEiy
MOLM-13 MnXjSpVv[3Srb36gRZN{[Xl? MmLPOuKh|ryP MnTGOkBp M2TQbmROW09? NI\YN4JmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw M3rWT|I1QDh3MEiy
HepG2 M{LNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NkBp NUXxTHJxTE2VTx?= MXrJR|UxRTN3Lki2JOKyKDJwOTFOwG0> MmHINlQ5QDR6MEm=
HepG2/As Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:3NkBp NVSwWJZbTE2VTx?= NUTacpljUUN3ME22PE4yOyEEsTC5MlYh|ryP MUmyOFg5PDhyOR?=
SMMC7721 NXXpV2ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrsdlhSPzJiaB?= M2fnTGROW09? MXHJR|UxRTNzLkK4JOKyKDRwMjFOwG0> MYKyOFg5PDhyOR?=
SMMC7721/Ac M4nWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\BXWo4OiCq MUHEUXNQ Mo\FTWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? MkjWNlQ5QDR6MEm=
Huh-7 NIrYXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q0SVczKGh? NFXDbZBFVVOR NVq4XHNCUUN3ME2zN{46PiEEsTCzMlkh|ryP NYXzeGN[OjR6OES4NFk>
Hep3B M2TXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;HPHo4OiCq M2nuNmROW09? NX3qbplJUUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?= MV:yOFg5PDhyOR?=
HepG2 NVPwb4dRSXCxcITvd4l{KEG|c3H5 MVvpcoR2[2W|IHHwc5B1d3Orcx?= M13Be|I1QDh2OEC5
SMMC7721 MX7BdI9xfG:|aYOgRZN{[Xl? MXPpcoR2[2W|IHHwc5B1d3Orcx?= M3\mVlI1QDh2OEC5
Huh-7 MWfBdI9xfG:|aYOgRZN{[Xl? M2nEU4lv\HWlZYOgZZBweHSxc3nz NHHIbXYzPDh6NEiwPS=>
Hep3B NETOUY9CeG:ydH;zbZMhSXO|YYm= NULnV28ycW6mdXPld{BieG:ydH;zbZM> NU\obY1vOjR6OES4NFk>
U2OS  M4nKVWZ2dmO2aX;uJGF{e2G7 NIjVeG4zOCEQvF2= NEfZSZAzPCCq NFnNPWRqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX M3rDU|I1QDZ5MkW5
AML2 MUfBdI9xfG:|aYOgRZN{[Xl? MnfNNk8yOCEQvF2= MXGyOE81QCCq Mlf6bY5lfWOnczDhdI9xfG:|aYO= M4KxXFI1PjV7N{S5
MOML13 Mme1RZBweHSxc3nzJGF{e2G7 M4Th[|IwOTBizszN M{fpTFI1NzR6IHi= MmPWbY5lfWOnczDhdI9xfG:|aYO= NGHv[WEzPDZ3OUe0PS=>
AML2 MV\GeY5kfGmxbjDBd5NigQ>? MYqxNO69VQ>? MmDFNk81KGh? Mo\wbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MljvNlQ3PTl5NEm=
AML3 MlvkSpVv[3Srb36gRZN{[Xl? MVSxNO69VQ>? MmjvNk81KGh? NH36eYRqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> M1\MO|I1PjV7N{S5
MOML13 MXvGeY5kfGmxbjDBd5NigQ>? M{W2NVEx|ryP MUOyM|QhcA>? M{PHeIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NUHDc|V7OjR4NUm3OFk>
BeWo NEfTZm9HfW6ldHnvckBCe3OjeR?= NILmZYU{OCEEtV2= M4[1WlI1KGh? M2XyW4lv[3KnYYPld{BxPTNuIF3kcVItKHB{MTDhcoQhWHWvYTDheEB1cGVicILveIVqdiCuZY\lcC=> NWnyTIxjOjR2OUixOVQ>
BeWo M2LhTGFxd3C2b4Ppd{BCe3OjeR?= NVTFR4t1OzBiwsXN Ml25NlQhcA>? NYS1fWFucW6lcnXhd4V{KGGyb4D0c5Nqew>? MYmyOFQ6QDF3NB?=
OCI NXjVWJlbTnWwY4Tpc44hSXO|YYm= NHHs[pIyOCEQvF2= NITJc4czPCCq NH7mN2p2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= M1jadFI1PDd|NU[y
MOLM MWfGeY5kfGmxbjDBd5NigQ>? MlPONVAh|ryP MkC2NlQhcA>? NGHt[Gl2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= NIH1fIgzPDR5M{W2Ni=>
U2OS  M1G4SGZ2dmO2aX;uJGF{e2G7 NWjHZVV1OjBizszN NILVRVczPCCq NUT3dYNVcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MVOyOFM3PjByNx?=
RKO NG\vdmpHfW6ldHnvckBCe3OjeR?= MV6yNEDPxE1? MXuyOEBp MVfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv M3zZfFI1OzZ4MEC3
U2OS  NWDTSpB{TnWwY4Tpc44hSXO|YYm= M3ixWlIxKM7:TR?= M1\mS|I1KGh? MVnpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NUnESmg5OjR|Nk[wNFc>
RKO NXntWm9xTnWwY4Tpc44hSXO|YYm= MljkNlAh|ryP NGjvPVYzPCCq MY\pcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= M2m1WVI1OzZ4MEC3
SMMC-7721  MkXpR4VtdCCYaXHibYxqfHliQYPzZZk> NFuwPVkyNjJ3LUKwJO69VQ>? M4DqT|I1NzR6L{eyJIg> NG[x[VBFVVOR MnzBbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MWCyOFI5PjNzMh?=
HuH-7 MknIR4VtdCCYaXHibYxqfHliQYPzZZk> M2\4UVEvOjVvMkCg{txO MXmyOE81QC95MjDo MmPMSG1UVw>? MWfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= M4TmclI1Ojh4M{Gy
SMMC-7721  MWnBdI9xfG:|aYOgRZN{[Xl? M{O4WlIxKM7:TR?= MUG0PEBp MY\EUXNQ MXfpcoR2[2W|IHHwc5B1d3Orcx?= NXrEXnJ{OjR{OE[zNVI>
HuH-7 MkXxRZBweHSxc3nzJGF{e2G7 NH:zXFYzOCEQvF2= NF;ZSpY1QCCq MoHLSG1UVw>? Mn76bY5lfWOnczDhdI9xfG:|aYO= MVmyOFI5PjNzMh?=
SMMC-7721  NX;wOGNkTnWwY4Tpc44hSXO|YYm= MUmxNEDPxE1? NVfofFNROzZiaB?= NWDMcJNzTE2VTx?= M1fTeYRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NYDSS5V2OjR{OE[zNVI>
HuH-7 MknLSpVv[3Srb36gRZN{[Xl? NXfLTJdDOTBizszN MoXYN|YhcA>? MXLEUXNQ MWjkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> NFy1SI8zPDJ6NkOxNi=>
AT2 NGi5WlRHfW6ldHnvckBCe3OjeR?= M1:5TVUwOTBizszN MnWzcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? MVmyOFI1ODJyMx?=
REH MYLGeY5kfGmxbjDBd5NigQ>? MX:1M|ExKM7:TR?= NE\ncWVt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MmXSNlQzPDB{MEO=
UoCB6 MXPGeY5kfGmxbjDBd5NigQ>? MYG1M|ExKM7:TR?= NV;VRotpdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= Mo\yNlQzPDB{MEO=
AT2 NX\ITGxRS2WubDDWbYFjcWyrdImgRZN{[Xl? NY\4ZXZ7OC1{NTFOwG0> M4HMRolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MoHBNlQzPDB{MEO=
REH M4f6OWNmdGxiVnnhZoltcXS7IFHzd4F6 MXSwMVI2KM7:TR?= MXTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M2OwfVI1OjRyMkCz
UoCB6 NF3w[VJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2\4UVAuOjVizszN M3jMfYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? Mny3NlQzPDB{MEO=
A2780 MmnFSpVv[3Srb36gRZN{[Xl? NWDNRnJFPS9zMD:yNEDPxE1? M2ThflI1KGh? NH7acZR2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NVi3WWhxOjRzM{[xOFc>
H460 NFTEcXJHfW6ldHnvckBCe3OjeR?= NVvkU3ZCPS9zMD:yNEDPxE1? NXLSVnBxOjRiaB?= MnPSeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? M{Pvc|I1OTN4MUS3
Lovo  Mom5SpVv[3Srb36gRZN{[Xl? Mn3XOU8yOC9{MDFOwG0> MWqyOEBp NFnLdG12eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MV:yOFE{PjF2Nx?=
A2780 MmLpRZBweHSxc3nzJGF{e2G7 NG\sVmM2NzFyL{KwJO69VQ>? MorHNlQhcA>? NUPXNnBG\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M3TlcVI1OTN4MUS3
H460 MXLBdI9xfG:|aYOgRZN{[Xl? NXjLZ2kzPS9zMD:yNEDPxE1? Mn3QNlQhcA>? MWrlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MYqyOFE{PjF2Nx?=
Lovo  M3TaT2Fxd3C2b4Ppd{BCe3OjeR?= MkniOU8yOC9{MDFOwG0> MnjlNlQhcA>? NWPuUnN6\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M3PrTVI1OTN4MUS3

... Click to View More Cell Line Experimental Data

体内研究 Nutlin-3 按200 mg/kg 剂量口服处理,每天两次,持续3周,显著抑制SJAS-1移植瘤生长,抑制达90%, 而Doxorubicin抑制81%肿瘤生长。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Biacore 研究:

在Biacore S51上进行竞争性实验。衍生一系列S传感器芯片CM5,用于固定 PentaHis抗体,为了捕获 His-标记的p53。捕获的水平为~200反应单位(1 反应单位对应于1 pg 蛋白/ mm2)。MDM2蛋白浓度一直维持在300 nM。Nutlin-3 溶于DMSO,浓度为10 mM,然后进一步稀释,在每个MDM2实验样本中产生系列浓度的Nutlin-3。在电泳缓冲液(10 mM Hepes,0.15 M NaCl, 2% DMSO)中25oC下进行实验。在Nutlin-3存在时,计算MDM2-p53结合情况,作为结合百分数, 使用Microsoft Excel计算IC50。
细胞实验:

[1]

+ 展开
  • Cell lines: HCT116, RKO, SJSA-1, SW480, 和 MDA-MB-435
  • Concentrations: 溶于DMSO,终浓度为~ 30 μM
  • Incubation Time: 8, 24, 和 48 小时
  • Method:

    使用不同浓度Nutlin-3处理细胞8, 24和 48 小时。通过实时PCR分析p21 和MDM2基因转录水平,通过Western Blotting分析蛋白水平。通过MTT实验测定细胞活力。 通过末端脱氧核苷酸转移酶调节的脱氧尿苷三磷酸缺口末端标记法(TUNEL)染色,使用流式细胞仪和荧光显微镜测定细胞凋亡。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 皮下注射 SJSA-1细胞的雌性无胸腺Nu/Nu-nuBR裸鼠
  • Formulation: 在 2% Klucel, 0.5% Tween-80配制中配制
  • Dosages: 200 mg/kg
  • Administration: 口服处理,每天两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.5
化学式

C30H30Cl2N4O4

CAS号 890090-75-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3 | Nutlin-3供应商 | 采购Nutlin-3 | Nutlin-3价格 | Nutlin-3生产 | 订购Nutlin-3 | Nutlin-3代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID